Exhibit 99.1
  

ISSUE 01 | FEBRUARY 2008
  
  

  
WELCOME
  
Welcome to Progen Pharmaceutical’s first ever edition of ‘Progen Press’. Through this publication we hope to
bring you further insight into what we do here at Progen and offer a new platform to communicate with our
audience.
  
This is a very exciting time for Progen as we begin the phase 3 clinical development of PI-88 and continue to
develop our discovery and preclinical programs whilst actively scanning the market for growth opportunities.
  
PROGEN MANAGEMENT TEAM
  
  
FINANCIAL OVERVIEW
  
· ASX (PGL) and NASDAQ (PGLA)
  
· Total number of fully paid ordinary shares on issue: 60.1M
  
· Total listed options outstanding: 2.97M
  
· Market capitalisation 31 Dec 2007: ~AU$ 151 million (~US$ 133 million)
  
  
  
THE
PROGEN
PRESS
 
 
This Edition
Progen Management Team
Financial Overview
Phase 3 Update
Corporate Overview
Profile Dr Laurence Marton
Progen’s New Technology
Progen’s Pipeline
Corporate Team
 
 
 
 
  
     
Justus Homburg
 
  CEO
Stephen Chang
 
  Executive Chairman
Linton Burns
 
  CFO / Company Secretary
Sarah Meibusch
 
  VP, Business Development
Dr James Garner
 
  VP, Clinical & Medical 
Dr Anand Gautam
 
  VP, Research
Dr Laurence Marton
 
  Chief Scientific Officer
Dr John Devlin
 
  VP, Operations
Staff numbers
 
  55 employees
· Cash on hand: ~AU$ 91 million as of December 31 2007 
  
PHASE 3 UPDATE
  
Progress continues apace on Progen’s global phase 3 study in Hepatocellular Carcinoma (HCC). The study now
has regulatory approval in almost half of the participating countries and more than a dozen sites have been
granted approval by ethics committees. Once a site has both regulatory approval and ethics approval, they are
able to begin recruiting patients. The first few sites are now online, and we expect our first patient to be enrolled
in the near future.
  
Progen is currently expecting to recruit about 65-70 sites into the study – slightly more than initially planned – due
to a greater-than-expected level of interest from investigators. We conducted regional launch meetings at the end
of 2007, and the enthusiasm of the clinicians has been most encouraging. We will be initiating each site as
regulatory and ethics approvals come through, and we look forward to working with leading clinicians in many of
the world’s top HCC treatment centres.
  
CORPORATE OVERVIEW
  
· Progen is a globally focused biotechnology company headquartered in Brisbane with an office in the San
Francisco bay area, USA.
  
· Progen is establishing itself as a leading biotech company with a long-term sustainable pipeline of products.
  
· PI-88 is a novel, first-in-class heparan sulfate mimetic with anti-metastatic and anti-angiogenic effects. It has
shown efficacy signals in the adjuvant treatment of HCC following surgical resection and is entering phase 3
trials in this indication.
  
· PI-88 is undergoing phase 2 development in melanoma and a small number of patients continue to receive
treatment in the prostate cancer trial. Recruitment in the melanoma trial is progressing according to plan and we
expect to complete the trial within the coming 12 months.
  
· Progen has recently added to its portfolio a phase 1 clinical candidate, PG11047, and a large platform of
preclinical epigenetics assets through the acquisition of Cellgate,Inc.
  

  
  
  
PROFILE
Dr Laurence Marton
  

  
As part of the acquisition of CellGate, Inc Progen has supplemented its management team with the appointment
of Dr Laurence Marton as Chief Scientific Officer.
  
Prior to joining Progen, Laurence Marton was the Chief Scientific Officer of CellGate and before that Chief
Scientific and Medical Officer of SLIL Biomedical Corporation. Both of these companies focused on the
discovery and development of novel polyamine analogs and other compounds for the treatment of cancer and
other serious diseases. Dr Marton co-founded and served as a director of SLIL.
  
Dr Marton was previously Dean of the University of Wisconsin-Madison Medical School and before that
Chaired the Department of Laboratory Medicine at the University of California, San Francisco. He is a leading
expert with extensive experience in the fields of cell growth and drug development. His work is focused on the
use of polyamines in treating human diseases related to aberrant cell growth, including cancer and infectious
diseases. His research has resulted in more than 180 original publications, 60 scientific reviews and chapters, four
books, and numerous patents, and his work has been acknowledged internationally.
  
Dr Marton serves as a consultant for industry and for governmental and academic institutions. He serves on the
Board of the Foundation for Cardiovascular and Transplant Research and was appointed by the Governor of
Wisconsin to the Wisconsin Technology Council. Dr Marton received his BA from Yeshiva University and his
MD from the Albert Einstein College of Medicine.
  
Dr Marton is based in Progen’s San Francisco office and we welcome him to the Progen team.
  
PROGEN’S
NEW TECHNOLOGY
  
Progen announced on February 4, 2008 that it had executed a Definitive Agreement to acquire privately-held
U.S. oncology company CellGate, Inc. The CellGate acquisition will expand Progen’s product candidate
portfolio through the addition of multiple pre-clinical and clinical oncology compounds focused on polyamine and
epigenetic targets.
  
Epigenetics, or the silencing of cancer related gene expression, is becoming a well-defined target in oncology and
Progen is excited to be entering this new frontier of cancer treatment.
  
For more information on the CellGate acquisition please visit the Progen website at www.progen-pharma.com or
phone + 61 7 3842 3333.
  
SAFE HARBOUR STATEMENT
  
This newsletter may contain forward-looking statements that are based on current management expectations.
These statements may differ materially from actual future events or results due to certain risks and uncertainties,
including without limitation, risks inherent in the extensive regulatory approval process mandated by the United
THE
PROGEN
PRESS
States Food and Drug Administration and the Australian Therapeutic Goods Administration prior to the
commercialization of any of our product candidates, including PI-88, the risk that the Phase 2 study results
described herein are not predictive of the Phase 3 studies which we intend to initiate, risks attendant to delays in
obtaining the necessary approvals for clinical testing of our product candidates, risks associated with delays in
patient recruitment for our planned Phase 3 clinical and other trials, delays in the conduct and completion of our
clinical trials, in particular our planned phase 3 clinical trials for PI-88, risks associated with our failure to
demonstrate adequate efficacy and safety data in our planned phase 3 clinical trials to advance the development
of PI-88, risks associated with our inability or failure to meet applicable regulatory standards and receive
regulatory approval for commercialization of PI-88, risks associated with the market acceptance of PI-88, PI-
166 and any of our other product candidates, if approved for commercialization, risks associated with our
inability to manufacture or otherwise obtain adequate supplies of PI-88, our future capital needs, general
economic conditions, and other risks and uncertainties detailed from time to time in our filings with the Australian
Securities Exchange and the United States Securities and Exchange Commission. Moreover, there can be no
assurance that others will not independently develop similar products or processes or design around patents
owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful
protection or competitive advantages.
  
PROGEN’S PIPELINE

  
Progen Pharmaceuticals Ltd ACN 010 975 612
Cindy Ingram Investor Relations
16 Benson St, Toowong, QLD 4066, Australia | PO Box 2403, Toowong, QLD 4066, Australia | T +61 7
3842 3333 | F +61 7 3720 9624